×
About 928 results

ALLMedicine™ Neovascular Glaucoma Center

Research & Reviews  299 results

Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
https://clinicaltrials.gov/ct2/show/NCT04519619

Jun 21st, 2022 - This is a prospective, observational, multi-center and post-authorization safety study that includes patients with a diagnosis of Neovascular Glaucoma. The investigator will have made the decision to use Eylea for treatment. The objective of this ...

XEN® 63 gel stent to treat a refractory uveitic glaucoma: A case report.
https://doi.org/10.1177/11206721221109199
European Journal of Ophthalmology; Serrar Y, Rezkallah A et. al.

Jun 18th, 2022 - To describe the effectiveness of the XEN® 63 gel stent in a refractory uveitic glaucoma after failure of an Ahmed Glaucoma Valve. We report the case of a 54-year-old man with a history of uveitic glaucoma on his left eye due to Fuchs heterochromic...

Ozurdex in Reducing PVR After Vitreotomy in PDR
https://clinicaltrials.gov/ct2/show/NCT05415826

Jun 13th, 2022 - Diabetic retinopathy is a significant source of visual morbidity in the adult population. Complications of diabetic retinopathy include ischemic maculopathy, macular edema, and sequelae of fibrovascular proliferation, such as vitreous hemorrhage (...

Clinical Manifestations of Supra-Large Range Nonperfusion Area in Diabetic Retinopathy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159255
International Journal of Clinical Practice; Tong N, Wang L et. al.

Jun 11th, 2022 - We describe the clinical manifestations of supra-large range nonperfusion area (SLRNPA) in diabetic retinopathy (DR). This was a retrospective case-control study. A total of 260 eyes of 236 patients with DR who underwent pars plana vitrectomy in t...

see more →

Clinicaltrials.gov  53 results

Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
https://clinicaltrials.gov/ct2/show/NCT04519619

Jun 21st, 2022 - This is a prospective, observational, multi-center and post-authorization safety study that includes patients with a diagnosis of Neovascular Glaucoma. The investigator will have made the decision to use Eylea for treatment. The objective of this ...

Ozurdex in Reducing PVR After Vitreotomy in PDR
https://clinicaltrials.gov/ct2/show/NCT05415826

Jun 13th, 2022 - Diabetic retinopathy is a significant source of visual morbidity in the adult population. Complications of diabetic retinopathy include ischemic maculopathy, macular edema, and sequelae of fibrovascular proliferation, such as vitreous hemorrhage (...

Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy
https://clinicaltrials.gov/ct2/show/NCT05414149

Jun 10th, 2022 - Proliferative diabetic retinopathy (PDR) is the most common causes of irreversible blindness in diabetic retinopathy (DR).It is characterized by progressive loss of vision, retinal edema, vitreous hemorrhage (VH), retinal neovascularization, fibro...

Comparison of Surgery Outcome Between Preoperative IVR and Intraoperative IVR in PPV for PDR
https://clinicaltrials.gov/ct2/show/NCT05408416

Jun 7th, 2022 - Proliferative diabetic retinopathy (PDR) is the most common causes of irreversible blindness in diabetic retinopathy (DR).It is characterized by progressive loss of vision, retinal edema, vitreous hemorrhage (VH), retinal neovascularization, fibro...

Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema
https://clinicaltrials.gov/ct2/show/NCT02985619

May 26th, 2022 - Methods Study Design. The current study is a prospective randomized clinical trial registered at ClinicalTrials.gov (NCT02985619). The study protocol adhered to the tenets of the Declaration of Helsinki and was approved by the local Institutional ...

see more →

News  19 results

Compliance in the Management of Diabetic Retinopathy: The Reality and Risk of Loss to Follow-up
https://www.staging.medscape.com/viewarticle/899649

Jul 27th, 2018 - Diabetes mellitus affects approximately 30 million people in the United States, or nearly 10% of the US population.[1] Diabetic retinopathy (DR)—retinal microvascular damage due to chronic hyperglycemia—is a leading cause of vision loss and ultima...

Compliance in the Management of Diabetic Retinopathy: The Reality and Risk of Loss to Follow-up
https://www.medscape.com/viewarticle/899649

Jul 27th, 2018 - Diabetes mellitus affects approximately 30 million people in the United States, or nearly 10% of the US population.[1] Diabetic retinopathy (DR)—retinal microvascular damage due to chronic hyperglycemia—is a leading cause of vision loss and ultima...

Anti-VEGF Treatment May Not Stop Diabetic Retinopathy
https://www.staging.medscape.com/viewarticle/884399

Aug 17th, 2017 - BOSTON — Vascular endothelial growth-factor (VEGF) inhibitors do not necessarily stop the progression of diabetic retinopathy in people with macular edema, new research shows. "We shouldn't forget that there are some people who aren't improved at ...

No Clear Differences in Shunts for Glaucoma
https://www.medpagetoday.com/ophthalmology/glaucoma/67243

Aug 12th, 2017 - Action Points Studies of aqueous shunts for glaucoma failed to demonstrate consistent advantages over standard surgery. Note that the study suggests that given that neither approach is perfect, ophthalmologists should individualize treatment to in...

Vancomycin-Related Cataract Surgery Complications Come Into Focus With Recent Data
https://www.medscape.com/viewarticle/878893

Apr 20th, 2017 - Vancomycin-Associated Hemorrhagic Occlusive Retinal Vasculitis: Clinical Characteristics of 36 Eyes Witkin AJ, Chang DF, Jumper JM, et al Ophthalmology. 2017 Jan 19. [Epub ahead of print] Study Summary Over the past few years, there has been incre...

see more →